JP2010527906A5 - - Google Patents

Download PDF

Info

Publication number
JP2010527906A5
JP2010527906A5 JP2009536266A JP2009536266A JP2010527906A5 JP 2010527906 A5 JP2010527906 A5 JP 2010527906A5 JP 2009536266 A JP2009536266 A JP 2009536266A JP 2009536266 A JP2009536266 A JP 2009536266A JP 2010527906 A5 JP2010527906 A5 JP 2010527906A5
Authority
JP
Japan
Prior art keywords
composition
glucan
antigen
cell
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009536266A
Other languages
English (en)
Japanese (ja)
Other versions
JP6082174B2 (ja
JP2010527906A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/023307 external-priority patent/WO2008057501A2/en
Publication of JP2010527906A publication Critical patent/JP2010527906A/ja
Publication of JP2010527906A5 publication Critical patent/JP2010527906A5/ja
Application granted granted Critical
Publication of JP6082174B2 publication Critical patent/JP6082174B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009536266A 2006-11-06 2007-11-06 免疫調節組成物及びその使用方法 Expired - Fee Related JP6082174B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US85683406P 2006-11-06 2006-11-06
US60/856,834 2006-11-06
US88038407P 2007-01-16 2007-01-16
US60/880,384 2007-01-16
US92975507P 2007-07-11 2007-07-11
US60/929,755 2007-07-11
PCT/US2007/023307 WO2008057501A2 (en) 2006-11-06 2007-11-06 Immunomodulating compositions and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2014022905A Division JP2014129366A (ja) 2006-11-06 2014-02-08 免疫調節組成物及びその使用方法
JP2016112724A Division JP2016188230A (ja) 2006-11-06 2016-06-06 免疫調節組成物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2010527906A JP2010527906A (ja) 2010-08-19
JP2010527906A5 true JP2010527906A5 (https=) 2011-04-14
JP6082174B2 JP6082174B2 (ja) 2017-02-15

Family

ID=39365102

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009536266A Expired - Fee Related JP6082174B2 (ja) 2006-11-06 2007-11-06 免疫調節組成物及びその使用方法
JP2014022905A Pending JP2014129366A (ja) 2006-11-06 2014-02-08 免疫調節組成物及びその使用方法
JP2016112724A Pending JP2016188230A (ja) 2006-11-06 2016-06-06 免疫調節組成物及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014022905A Pending JP2014129366A (ja) 2006-11-06 2014-02-08 免疫調節組成物及びその使用方法
JP2016112724A Pending JP2016188230A (ja) 2006-11-06 2016-06-06 免疫調節組成物及びその使用方法

Country Status (5)

Country Link
US (1) US8580253B2 (https=)
EP (1) EP2066294B9 (https=)
JP (3) JP6082174B2 (https=)
ES (1) ES2397186T3 (https=)
WO (1) WO2008057501A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457047B2 (en) * 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
EP2283358B1 (en) 2008-04-29 2015-04-22 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP2012205656A (ja) * 2011-03-29 2012-10-25 Kyocera Medical Corp 生体インプラント用被覆材料、およびインプラント
WO2012139089A2 (en) 2011-04-08 2012-10-11 The General Hospital Corporation Fungal-derived carbohydrate-conjugated scaffold
WO2012154818A1 (en) * 2011-05-09 2012-11-15 Biothera, Inc. B-glucan compounds, compositions, and methods
WO2012167061A1 (en) * 2011-06-03 2012-12-06 Biothera, Inc. OPSONIZED β-GLUCAN PREPARATIONS AND METHODS
WO2015053354A1 (ja) * 2013-10-09 2015-04-16 東レ株式会社 免疫賦活化剤
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
KR102717969B1 (ko) 2014-02-21 2024-10-15 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
AU2015255823A1 (en) * 2014-05-08 2016-11-10 Immunexcite, Inc. Immunomodulating beta-1,6-D-glucans
US9480656B1 (en) 2015-09-28 2016-11-01 King Saud University Method of preparing rosemary nanoparticles and encapsulated rosemary nanoparticles
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
CN113966227B (zh) 2019-02-15 2025-10-10 克利夫兰诊所基金会 疫苗佐剂以及制剂
US20220233756A1 (en) * 2019-05-17 2022-07-28 George A. Herzlinger Methods and systems for treating microbial disease
EP4096685A1 (en) * 2020-01-29 2022-12-07 Pleuran, s.r.o. Beta-glucan for use in modulation of an immune response in a remission
EP3858362A1 (en) * 2020-01-29 2021-08-04 Pleuran, s.r.o. Beta-glucan for use in enhancement of anti-tumor immunity in remission

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) * 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4590181A (en) * 1982-12-20 1986-05-20 Board Of Regents Of The University Of Nebraska Synthetic immunoregulators and methods of use and preparation
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4992540A (en) * 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
AU650626B2 (en) * 1989-09-08 1994-06-30 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
WO1991003248A2 (en) * 1989-09-08 1991-03-21 Alpha Beta Technology, Inc. Method for immune system activation
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) * 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
NO300692B1 (no) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US6048551A (en) * 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
US6046323A (en) * 1997-07-29 2000-04-04 The Collaborative Group, Ltd. Conformations of PPG-glucan
US6468519B1 (en) * 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US6486214B1 (en) * 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
AU6261999A (en) * 1998-09-25 2000-04-17 Collaborative Group, Ltd., The Very high molecular weight beta-glucans
US6328988B1 (en) * 1999-04-23 2001-12-11 Rutgers, The State University Of New Jersey Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US20040127458A1 (en) * 2000-11-06 2004-07-01 Hunter Kenneth W. Beta-glucan containing compositions, methods for manufacturing beta-glucans, and for manufacturing and using beta-glucans and conjugates thereof as vaccine adjuvants
US6476003B1 (en) * 2000-11-06 2002-11-05 Immusonic, Inc. Method for preparing small particle size glucan in a dry material
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20050191361A1 (en) * 2001-08-03 2005-09-01 Powederject Research Ltd. Hydrogel particle formation
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
WO2004030613A2 (en) * 2002-09-04 2004-04-15 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
US7060299B2 (en) * 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
WO2007033315A1 (en) * 2005-09-14 2007-03-22 Whitehead Institute For Biomedical Research Drug induced exposure of the fungal pro-inflammatory molecule beta-glucan
WO2008027580A2 (en) * 2006-09-01 2008-03-06 University Of Louisville PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS
EP2283358B1 (en) 2008-04-29 2015-04-22 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2010527906A5 (https=)
Gopi et al. Effective drug delivery system of biopolymers based on nanomaterials and hydrogels-a review
Zhao et al. Neoantigen immunotherapeutic-gel combined with TIM-3 blockade effectively restrains orthotopic hepatocellular carcinoma progression
JP6082174B2 (ja) 免疫調節組成物及びその使用方法
Jia et al. Potential applications of nanoparticles in cancer immunotherapy
Zhang et al. PEI-modified macrophage cell membrane-coated PLGA nanoparticles encapsulating Dendrobium polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses
Liu et al. Lentinan-functionalized graphene oxide is an effective antigen delivery system that modulates innate immunity and improves adaptive immunity
JP2009080118A5 (https=)
JPH01294636A (ja) 新規の高分子免疫アジュバント
Hosseinpour et al. Modulating osteoimmune responses by mesoporous silica nanoparticles
Chen et al. Pollen-mimetic metal–organic frameworks with tunable spike-like nanostructures that promote cell interactions to improve antigen-specific humoral immunity
Wang et al. MWCNT-mediated combinatorial photothermal ablation and chemo-immunotherapy strategy for the treatment of melanoma
AU2017375793B2 (en) Microparticles and nanoparticles having negative surface charges
JP7570134B2 (ja) 治療用ワクチンとしての使用のためのナノ粒子
Yu et al. Quaternized chitosan nanoparticles in vaccine applications
Puri et al. Overview of mucoadhesive biopolymers for buccal drug delivery systems
US8399025B2 (en) Polyamine modified particles
Singh et al. Enhancement of mucoadhesive property of polymers for drug delivery applications
Wang et al. Vaccine nanoparticles derived from mung beans for cancer immunotherapy
Masimov et al. Chitosan non-particulate vaccine delivery systems
Oluwole et al. Design principles for immunomodulatory biomaterials
CN105611936A (zh) 免疫增强剂
Wang et al. Personalized tumor vaccines based on carrier-free double-adjuvant nanoparticles and tumor-associated antigens for enhancing immune responses
US20210353745A1 (en) Methods and reagents to treat allergy
Zhang et al. Self-assembling sulfated Lactobacillus exopolysaccharide nanoparticles as adjuvants for SARS-CoV-2 subunit vaccine elicit potent humoral and cellular immune responses